NCT07161869Recruiting
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma by Endoscopic Ultrasound (POELH-III)
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
In the POELH-II trial (Clinicaltrials.gov ID NCT05678218) patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct (CBD) cholangiocarcinoma had the outcomes of their preoperative endoscopic ultrasound (EUS) registered. This EUS procedure was done systematically, targeting lymph nodes (LNs) with the aim to identify LN metastases preoperatively. The goal of this follow-up observational cohort study (POELH-III) is to assess the yield of preoperative EUS, with an improved EUS approach. The EUS protocol as used in the POELH-II trial was improved based on preliminary results of the POELH-II trial. The main questions it aims to answer is: \- The number of patients precluded from surgical work-up due to positive regional or extraregional LNs identified by EUS guided tissue acquisition
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 28 Aug 2025
- Start date
- 5 Feb 2026
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07161869
What you commit to
- Study type: Observational
- Planned participants: 250
- From 5 Feb 2026 to the primary completion date, 1 Oct 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of treated CCA
- Patients with a history of treated liver malignancy
Lab values
- Patients with a contra-indication for EUS-tissue acquisition (f.e. uncorrectable coagulopathy or platelet disorder), in line with current clinical practice
Other
- Patients with CCA for which a pancreatoduodenectomy is indicated, based on cross-sectional imaging
Who the study is looking for
- Presumed resectable pCCA OR
- Presumed resectable iCCA OR
- Presumed resectable mid-common bile duct CCA OR
- Presumed unresectable pCCA worked-up for Liver Transplantation AND
- Written informed consent must be given according to International Council on Harmonisation/Good Clinical Practice guidelines, and national/local regulations AND
- Age \> 18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Center Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Not yet recruiting |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Not yet recruiting |
| Leiden University Medical Center Coordinator of this site? Confirm its status | Leiden | Netherlands | Not yet recruiting |
| Maastricht University Medical Center Coordinator of this site? Confirm its status | Maastricht | Netherlands | Not yet recruiting |
| Erasmus MC University Medical Center Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
| University Medical Center Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.